Fujito Ohwaki - Kobayashi Pharmaceutical Sr Division
| KBYPFDelisted Stock | USD 32.49 0.00 0.00% |
Insider
Fujito Ohwaki is Sr Division of Kobayashi Pharmaceutical Co
| Phone | 81 6 6222 0142 |
| Web | https://www.kobayashi.co.jp |
Kobayashi Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0633 % which means that it generated a profit of $0.0633 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0968 %, meaning that it generated $0.0968 on every $100 dollars invested by stockholders. Kobayashi Pharmaceutical's management efficiency ratios could be used to measure how well Kobayashi Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Kobayashi Pharmaceutical Co has accumulated 596 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Kobayashi Pharmaceutical has a current ratio of 3.84, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Kobayashi Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Kobayashi Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kobayashi Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kobayashi to invest in growth at high rates of return. When we think about Kobayashi Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Victor Aguilar | Procter Gamble | 53 | |
| William Trousdale | Sun Country Airlines | 55 | |
| Makela Taphorn | Artisan Partners Asset | N/A | |
| Weichou Su | Stepstone Group | 66 | |
| Darren Friedman | Stepstone Group | 56 | |
| Feng Li | Yuexiu Transport Infrastructure | 54 | |
| M Grabowski | Procter Gamble | 52 | |
| Jing Chen | Yuexiu Transport Infrastructure | 50 | |
| John Gyurci | Sun Country Airlines | 53 | |
| CPA Daley | Artisan Partners Asset | 61 | |
| Loic Tassel | Procter Gamble | N/A | |
| Jeffrey Mader | Sun Country Airlines | 63 | |
| Lindsay Creedon | Stepstone Group | 47 | |
| Kelsey DodsonSmith | Sun Country Airlines | N/A | |
| Thomas Finn | Procter Gamble | N/A | |
| Christine McCarthy | Procter Gamble | 65 | |
| Jude Bricker | Sun Country Airlines | 50 | |
| Jennifer Davis | Procter Gamble | 52 | |
| Jose JD | Stepstone Group | 53 | |
| Johnny Randel | Stepstone Group | 59 | |
| Minghua Cai | Yuexiu Transport Infrastructure | 44 | |
Management Performance
| Return On Equity | 0.0968 | |||
| Return On Asset | 0.0633 |
Kobayashi Pharmaceutical Leadership Team
Elected by the shareholders, the Kobayashi Pharmaceutical's board of directors comprises two types of representatives: Kobayashi Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kobayashi. The board's role is to monitor Kobayashi Pharmaceutical's management team and ensure that shareholders' interests are well served. Kobayashi Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kobayashi Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Takayuki Kimura, Gen Department | ||
| Tetsuji Nishioka, Sr Headquarters | ||
| Yoshihiro Ogawa, Sr Division | ||
| Naoki Ayabe, GM Area | ||
| Satoshi Yamane, Managing Director, Executive Officer, Chief Senior Director of Headquarter Group | ||
| Kazumasa Kobayashi, Chairman of the Board, Chairman of Subsidiary, Representative Director | ||
| Akihiro Kobayashi, President Executive Officer, Representative Director | ||
| Fujito Ohwaki, Sr Division | ||
| Kazuhito Miyanishi, Executive Officer, Director of International Business | ||
| Takuya Matsushita, Sr Division |
Kobayashi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kobayashi Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0968 | |||
| Return On Asset | 0.0633 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 3.94 B | |||
| Shares Outstanding | 76.01 M | |||
| Shares Owned By Insiders | 34.50 % | |||
| Shares Owned By Institutions | 21.77 % | |||
| Price To Earning | 34.29 X | |||
| Price To Book | 2.85 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Kobayashi Pink Sheet
If you are still planning to invest in Kobayashi Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kobayashi Pharmaceutical's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |